Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Belviq

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
A recent lorcaserin trial investigated ‘the long-term cardiovascular and metabolic safety and efficacy of lorcaserin’ in subjects… Expand
2018
2018
Serotonin (5-hydroxytryptamine; 5-HT) was identified in the mammalian brain in the 1950s. We now recognize brain 5-HT to… Expand
  • figure 1
2016
2016
  • JAMA
  • 2016
  • Corpus ID: 33266011
Drugs for Weight Loss Pharmacologic treatment of obesity has been limited by modest efficacy, adverse effects, low adherence… Expand
  • table 1
  • table 2
2014
2014
Lorcaserin, combined with diet and exercise, can be used to produce additional weight loss, although the effect on morbidity and… Expand
Review
2014
Review
2014
Review Article Obesity has become a global problem, affecting countries which are developed and developing. One of the most… Expand
  • table 1
Review
2014
Review
2014
Obesity is a risk factor for a wide range of conditions, including cardiovascular disease. Although lifestyle modifications… Expand
Review
2014
Review
2014
The pharmacotherapy of obesity has historically recorded an overall poor safety and efficacy profile largely because of the… Expand
2013
2013
In the U.S., obesity is prevalent in epidemic proportions, and rates continue to rise. Current data indicate that the combined… Expand
  • figure 1
  • table 1
2012
2012
New molecular entity: FDA approved Lorcaserin (Belviq, Arena Pharmaceuticals GMBH), as an adjunct to a reduced-calorie diet and… Expand